var data={"title":"Alfacalcidol (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alfacalcidol (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/426410?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alfacalcidol-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alfacalcidol (United States: Not available): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11820952\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>One-Alpha</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11820954\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vitamin D Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821507\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic kidney disease-mineral and bone disorder (hypocalcemia, secondary hyperparathyroidism, or osteodystrophy): </b>\n      <b>Note:</b> Patients taking calcium supplements should limit intake to &le;500 mg/day (elemental calcium).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Predialysis patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 0.25 mcg/day for 2 months; if necessary, may titrate dose upward in increments of 0.25 mcg/day every 2 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance (usual dose): 0.5 mcg/day; up to 1 mcg/day may be necessary to maintain desired serum calcium concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 1 mcg/day for up to 4 weeks; if necessary, may titrate dose upward in increments of 0.5 mcg/day every 2 to 4 weeks. Usual effective dose: 1 to 2 mcg/day; up to 3 mcg/day may be required in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance (usual dose): 0.25 to 1 mcg/day; dosing interval may be increased (every other day or less frequently) in patients who develop hypercalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> In some studies, intermittent dosing (on dialysis days) in dialysis patients has been shown as efficacious as daily dosing (Tarrass 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>IV:</i> Dialysis patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 1 mcg per dialysis (2 to 3 times weekly); if inadequate response after 1 week, may titrate dose upward in weekly increments of 1 mcg per dialysis (maximum dose: 12 mcg/week). Total titration period should not exceed 6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: 1.5 to 12 mcg per week (divided equally between hemodialysis sessions); usual effective dose: 6 mcg/week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671343\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671344\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821508\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Predialysis patients: If hypercalcemia develops within the first 2 months of therapy reduce dose to 0.25 mcg every other day; at any other time during therapy,  reduce dose by 50% and discontinue all calcium supplements until serum calcium levels normalize. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Dialysis patients: Oral, IV: Discontinue immediately for hypercalcemia; may consider reintroducing therapy at a reduced dose after serum calcium levels normalize. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821726\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, softgel, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">One-Alpha: 0.25 mcg, 1 mcg  [contains sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">One-Alpha: 2 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, oral [drops]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">One-Alpha: 2 mcg/mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11820951\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821509\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer oral solution (drops) and capsules with or without food and/or drink. Do not shake oral solution bottle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Shake injection solution well prior to use and administer as bolus IV injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11820955\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic kidney disease-mineral and bone disorder:</b> Management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11820949\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Alfacalcidol may be confused with calcitriol, cholecalciferol, ergocalciferol, paricalcitol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821491\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Frequency not defined; as associated with Hypervitaminosis D. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, hypertension </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, hyperthermia, psychosis (rare), drowsiness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation, dysgeusia, nausea, pancreatitis, vomiting, xerostomia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Nocturia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, hypercalcemia, hypercholesterolemia, hyperphosphatemia, polydipsia, weight loss </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myalgia, ostealgia, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis, corneal deposits (calcification), photophobia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, polyuria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Rhinorrhea </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11820958\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to 1-&alpha;-hydroxyvitamin D<sub>3</sub>, vitamin D or its analogues and derivatives, or any component of the formulation; hypercalcemia; hyperphosphatemia; evidence of vitamin D toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821489\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of parathyroid hormone (PTH), progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia: Monitor calcium levels closely; patients with chronic renal failure are at an increased risk for hypercalcemia. Dose reduction or discontinuation of therapy may be necessary. Withhold calcium supplementation until calcium levels normalize. Discontinue use with hypercalcemia in dialysis patients; may reinstitute therapy at 50% of previous dose 1 week after calcium levels have normalized. Chronic hypercalcemia may result in generalized vascular and soft tissue calcification and exacerbate nephrolithiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperphosphatemia: Monitor serum phosphate; hyperphosphatemia may require the use of phosphate-binding agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular: Avoid prolonged hypercalcemia; may aggravate arteriosclerosis or cardiac valve sclerosis. Use with caution in patients with calcification of pulmonary tissue; may result in cardiac disease. Severe hypercalcemia may increase risk of cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Granulomatous diseases: Use with caution in patients with granulomatous diseases (eg, sarcoidosis) due to increased sensitivity to vitamin D.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298703\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11822195\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16467&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Alfacalcidol may increase the serum concentration of Magnesium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11820956\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21098355\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Alfacalcidol may be present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821497\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Adequate dietary calcium is necessary for clinical response to vitamin D. Recommended daily allowance of calcium in adults: 800-1000 mg (from all sources of calcium intake such as dialysate, diet and calcium supplements). Patients taking calcium supplements should limit intake to &le;500 mg/day (elemental calcium) during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821516\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 3: Every 6 to 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 4: Every 3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD stage 5 and 5D: Every 1 to 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periodic 24-hour urinary calcium and phosphorus; magnesium; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH; creatinine, BUN, albumin; intact parathyroid hormone (iPTH) every 3 to 12 months depending on CKD severity; periodic ophthalmologic exams; symptoms of hypercalcemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821515\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus (K/DOQI, 2003): CKD stages 3 and 4: 2.7-4.6 mg/dL (0.87-1.48 mmol/L); CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium-phosphorus product (K/DOQI, 2003): CKD stage 3-5: &lt;55 mg<sup>2</sup>/dL<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0-5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0-65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0-6.0 pmol/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for the assay used</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821701\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alfacalcidol is rapidly converted to the active metabolite of vitamin D (1,25-dihydroxyvitamin D<sub>3</sub>) in the liver, effectively bypassing renal metabolic conversion; promotes intestinal absorption of calcium and phosphorous, resorption of calcium from the bone, and possibly renal reabsorption of calcium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11821498\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of effect on intestinal calcium absorption levels: 1,25-(OH)<sub>2</sub> D<sub>3</sub>: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Extensively to vitamin D-binding protein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to 1,25-(OH)<sub>2</sub> D<sub>3</sub></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~3 hours in renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak of active vitamin D levels: Oral: 12 hours; IV: 4 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14190114\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>1 Alpha Leo (BE);</li>\n      <li>Alcidol (TH);</li>\n      <li>Alfa Caps (IN);</li>\n      <li>Alfa D (CR, DO, GT, HN, MT, NI, PA, SV);</li>\n      <li>Alfacan (CN);</li>\n      <li>Alfadiol (PL);</li>\n      <li>Alfaget (LK);</li>\n      <li>Alfarol (JP, TW);</li>\n      <li>Alpha D3 (AR, CZ, EE, GR, HK, HR, IL, IT, LI, LT, LV, PH, PY, RO, RU, SG, SI, SK, TR, UA, VE, VN);</li>\n      <li>Alpha-D3 (LK);</li>\n      <li>Alphacal (GR);</li>\n      <li>Bon-One (CN, HK, ID, MY, TH);</li>\n      <li>Bondiol (DE);</li>\n      <li>Bone-One (VN);</li>\n      <li>Calcicure (LK);</li>\n      <li>EinsAlpha (DE);</li>\n      <li>Etalpha (AT, CL, CN, DK, ES, FI, IS, LI, NL, NO, PT, RU, SE);</li>\n      <li>Gr-Alfa (IN);</li>\n      <li>Innosfen (BR, PY);</li>\n      <li>Losefan (GR);</li>\n      <li>Lusefan (LI);</li>\n      <li>One Alpha (LK);</li>\n      <li>One-Alpha (AE, CY, EG, GB, HK, IE, JO, KW, LB, LT, MT, MY, NZ, PL, QA, RO, RU, SA, SG, TH, TR, ZA);</li>\n      <li>Onealfa (JP, KR, TW);</li>\n      <li>Ostidil-D3 (IT);</li>\n      <li>QTR-Alfa (IN);</li>\n      <li>Sundiol (SK);</li>\n      <li>Tevacidol (DE);</li>\n      <li>Un Alfa (FR);</li>\n      <li>Xbone (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Hamdy N, Kanis JA, Beneton MN, et al, &ldquo;Effect of Alfacalcidol on Natural Course of Renal Bone Disease in Mild to Moderate Renal Failure,&rdquo; <i>BMJ</i>, 1995, 310(6976):358-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/7677827/pubmed\" target=\"_blank\" id=\"7677827\">7677827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 1. Evaluation of Calcium and Phosphorus Metabolism.&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide1.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 3. Evaluation of Serum Phosphorus Levels.&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide3.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 6. Serum Calcium and Calcium-Phosphorus Product.&rdquo; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide6.htm14520607</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 8A. Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD.&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide8A.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 8B. Vitamin D Therapy in Patients on Dialysis (CKD Stage 5).&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide8B.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, &quot;KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease,&quot;<i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, &quot;KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),&quot; <i>Kidney Int Suppl</i>, 2009, 76(S113):1-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/19644521/pubmed\" target=\"_blank\" id=\"19644521\">19644521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levin A, Hemmelgarn B, Culleton B, et al, &ldquo;Canadian Guidelines for the Management of Chronic Kidney Disease,&rdquo; <i>CMAJ</i>, 2008, 179(11):1154-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/19015566/pubmed\" target=\"_blank\" id=\"19015566\">19015566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    One-Alpha (alfacalcidol) [product monograph]. Thornhill, Ontario, Canada: LEO Pharma Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    One-Alpha Injection (alfacalcidol) [summary of product characteristics]. Berkshire, United Kingdom: LEO Laboratories Limited; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tarrass F, Yazidi A, Sif H, et al, &ldquo;A Randomized Trial of Intermittent Versus Continuous Oral Alfacalcidol Treatment of Hyperparathyroidism in End-Stage Renal Disease,&rdquo; <i>Clin Nephrol</i>, 2006, 65(6):415-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/16792136/pubmed\" target=\"_blank\" id=\"16792136\">16792136</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16467 Version 72.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11820952\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F11820954\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F11821507\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671343\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671344\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F11821508\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F11821726\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11820951\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11821509\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F11820955\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11820949\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11821491\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11820958\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11821489\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298703\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11822195\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11820956\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21098355\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F11821497\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11821516\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F11821515\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11821701\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11821498\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F14190114\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16467|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alfacalcidol-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Alfacalcidol (United States: Not available): Patient drug information \t</a></li></ul></div></div>","javascript":null}